An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Therapeutic Use
- 05 Jul 2018 Status changed from not yet recruiting to recruiting.
- 13 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 15 Feb 2018.
- 07 Feb 2018 New trial record